Dual-hormone treatment with insulin and glucagon in patients with type 1 diabetes

H K Reiband; S Schmidt; Ajenthen Ranjan; Jens Juul Holst; S Madsbad; K Nørgaard

doi:10.1002/dmrr.2632

Dual-hormone treatment with insulin and glucagon in patients with type 1 diabetes

H K Reiband, S Schmidt, Ajenthen Ranjan, Jens Juul Holst, S Madsbad, K Nørgaard

10 Citations (Scopus)

Abstract

Intensive insulin treatment in type 1 diabetes reduces the incidence and slows the progression of microvascular and macrovascular complications; however, it is associated with an increased risk of hypoglycaemia and weight gain. In this review, we propose dual-hormone treatment with insulin and glucagon as a method for achieving near normalization of blood glucose levels without increasing hypoglycaemia frequency and weight gain. We briefly summarize glucagon pathophysiology in type 1 diabetes as well as the current applications of glucagon for the treatment of hypoglycaemia. Until now, the use of glucagon has been limited by the need for reconstitution immediately before use, because of instability of the available compounds; however, stabile compounds are soon to be launched and will render long-term intensive dual-hormone treatment in type 1 diabetes possible.

Original language	English
Journal	Diabetes - Metabolism: Research and Reviews (Print Edition)
Volume	31
Issue number	7
Pages (from-to)	672-9
Number of pages	8
ISSN	1520-7552
DOIs	https://doi.org/10.1002/dmrr.2632
Publication status	Published - Oct 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/dmrr.2632

Cite this

@article{8e48c0892e9e4dbb98459fb40a9ee90c,

title = "Dual-hormone treatment with insulin and glucagon in patients with type 1 diabetes",

abstract = "Intensive insulin treatment in type 1 diabetes reduces the incidence and slows the progression of microvascular and macrovascular complications; however, it is associated with an increased risk of hypoglycaemia and weight gain. In this review, we propose dual-hormone treatment with insulin and glucagon as a method for achieving near normalization of blood glucose levels without increasing hypoglycaemia frequency and weight gain. We briefly summarize glucagon pathophysiology in type 1 diabetes as well as the current applications of glucagon for the treatment of hypoglycaemia. Until now, the use of glucagon has been limited by the need for reconstitution immediately before use, because of instability of the available compounds; however, stabile compounds are soon to be launched and will render long-term intensive dual-hormone treatment in type 1 diabetes possible.",

author = "Reiband, {H K} and S Schmidt and Ajenthen Ranjan and Holst, {Jens Juul} and S Madsbad and K N{\o}rgaard",

note = "Copyright {\textcopyright} 2014 John Wiley & Sons, Ltd.",

year = "2015",

month = oct,

doi = "10.1002/dmrr.2632",

language = "English",

volume = " 31",

pages = "672--9",

journal = "Diabetes/Metabolism Research and Reviews",

issn = "1520-7552",

publisher = "Wiley",

number = "7",

}

TY - JOUR

T1 - Dual-hormone treatment with insulin and glucagon in patients with type 1 diabetes

AU - Reiband, H K

AU - Schmidt, S

AU - Ranjan, Ajenthen

AU - Holst, Jens Juul

AU - Madsbad, S

AU - Nørgaard, K

PY - 2015/10

Y1 - 2015/10

N2 - Intensive insulin treatment in type 1 diabetes reduces the incidence and slows the progression of microvascular and macrovascular complications; however, it is associated with an increased risk of hypoglycaemia and weight gain. In this review, we propose dual-hormone treatment with insulin and glucagon as a method for achieving near normalization of blood glucose levels without increasing hypoglycaemia frequency and weight gain. We briefly summarize glucagon pathophysiology in type 1 diabetes as well as the current applications of glucagon for the treatment of hypoglycaemia. Until now, the use of glucagon has been limited by the need for reconstitution immediately before use, because of instability of the available compounds; however, stabile compounds are soon to be launched and will render long-term intensive dual-hormone treatment in type 1 diabetes possible.

AB - Intensive insulin treatment in type 1 diabetes reduces the incidence and slows the progression of microvascular and macrovascular complications; however, it is associated with an increased risk of hypoglycaemia and weight gain. In this review, we propose dual-hormone treatment with insulin and glucagon as a method for achieving near normalization of blood glucose levels without increasing hypoglycaemia frequency and weight gain. We briefly summarize glucagon pathophysiology in type 1 diabetes as well as the current applications of glucagon for the treatment of hypoglycaemia. Until now, the use of glucagon has been limited by the need for reconstitution immediately before use, because of instability of the available compounds; however, stabile compounds are soon to be launched and will render long-term intensive dual-hormone treatment in type 1 diabetes possible.

U2 - 10.1002/dmrr.2632

DO - 10.1002/dmrr.2632

M3 - Review

C2 - 25533565

SN - 1520-7552

VL - 31

SP - 672

EP - 679

JO - Diabetes/Metabolism Research and Reviews

JF - Diabetes/Metabolism Research and Reviews

IS - 7

ER -

Dual-hormone treatment with insulin and glucagon in patients with type 1 diabetes

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this